Kronos Bio, Inc. (KRON) Tops Q2 EPS by 9c

Kronos Bio, Inc. (NASDAQ: KRON) reported Q2 EPS of ($0.27), $0.09 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $2.69 million versus the consensus estimate of $1.53 million.

For earnings history and earnings-related data on Kronos Bio, Inc. (KRON) click here.

You May Also Be Interested In

• Bright Horizons Family Solutions (BFAM) Tops Q2 EPS by 8c; offers guidance
• Forum Energy Technologies (FET) Tops Q2 EPS by 65c; offers guidance
• JPMorgan Downgrades Gruma SAB de CV (GRUMAB:MM) (GPAGF) to Underweight